Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TSHA Taysha Gene Therapies, Inc.

Market Closed 01-16 16:00:00 EST

4.56

-0.34

-6.94%

盘后4.59

+0.03+0.66%

19:57 EST

High4.97	Low4.49	Vol3.72M
Open4.93	D1 Closing4.90	Amplitude9.90%
Mkt Cap1.25B	Tradable Cap839.04M	Total Shares273.92M
T/O17.29M	T/O Rate2.02%	Tradable Shares184.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TSHA","market":"US","secType":"STK","nameCN":"Taysha Gene Therapies, Inc.","latestPrice":4.56,"timestamp":1768597200000,"preClose":4.9,"halted":0,"volume":3715501,"hourTrading":{"tag":"盘后","latestPrice":4.59,"preClose":4.56,"latestTime":"19:57 EST","volume":247853,"amount":1130437.363,"timestamp":1768611455478},"delay":0,"floatShares":184000000,"shares":273919373,"eps":-0.335921,"marketStatus":"Market Closed","change":-0.34,"latestTime":"01-16 16:00:00 EST","open":4.93,"high":4.97,"low":4.485,"amount":17291168.829792,"amplitude":0.09898,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.335921,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"listingDate":1600920000000,"exchange":"NASDAQ","adjPreClose":4.9,"preHourTrading":{"tag":"盘前","latestPrice":4.9589,"preClose":4.9,"latestTime":"08:33 EST","volume":208,"amount":1023.4189264,"timestamp":1768570387828},"postHourTrading":{"tag":"盘后","latestPrice":4.59,"preClose":4.56,"latestTime":"19:57 EST","volume":247853,"amount":1130437.363,"timestamp":1768611455478},"volumeRatio":1.352760431614564,"impliedVol":1.1935,"impliedVolPercentile":0.6175},"requestUrl":"/m/hq/s/TSHA/tweets","defaultTab":"tweets","newsList":[{"id":"2601400817","title":"Taysha Gene Therapies Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601400817","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601400817?lang=en_us&edition=fundamental","pubTime":"2026-01-07 03:19","pubTimestamp":1767727140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TSHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 14:19 ET (19:19 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"gpt_icon":0},{"id":"2601897130","title":"Taysha Gene Therapies Doses First Patient in Pivotal Rett Syndrome Gene Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897130","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897130?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:03","pubTimestamp":1767704585,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies Inc. has announced progress in its TSHA-102 pivotal gene therapy program for Rett syndrome. The company recently dosed the first patient in the REVEAL pivotal trial, which will enroll 15 female patients aged 6 to under 22 years. The trial is evaluating a single intrathecal administration of TSHA-102, an AAV9-based gene therapy, with response rate as the primary endpoint. Additionally, Taysha has reached written alignment with the FDA to include at least three months of safety data from the ASPIRE trial, involving patients aged 2 to under 4 years, in its planned Biologics License Application  submission. Completion of dosing in both the REVEAL and ASPIRE trials is expected in the second quarter of 2026. Longer-term safety and efficacy data from Part A of the REVEAL Phase 1/2 trials are expected to be available in the first half of 2026. Results from the trials have not yet been presented.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL2PjR9l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","TSHA","BK4112","BK4585","LU2210149790.SGD","SG9999014021.USD","BK4588","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD"],"gpt_icon":0},{"id":"2601897589","title":"Taysha Gene Therapies Announces Progress Across Tsha-102 Pivotal Gene Therapy Program in Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897589?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:00","pubTimestamp":1767704409,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA3FQQKZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TSHA","BK4139"],"gpt_icon":0},{"id":"2601897578","title":"Taysha Gene Therapies : Longer-Term Safety & Efficacy Data Update From Part a of Reveal Phase 1/2 Trials Expected in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897578?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:00","pubTimestamp":1767704409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA3FQQKZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TSHA","BK4139"],"gpt_icon":0},{"id":"2601576897","title":"Taysha Gene Therapies: Completion of Dosing in Reveal Pivotal Trial & Aspire Trial Expected in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601576897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601576897?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:00","pubTimestamp":1767704409,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA3FQQKZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TSHA","BK4139"],"gpt_icon":0},{"id":"2601831659","title":"Taysha Gene Therapies Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2601831659","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601831659?lang=en_us&edition=fundamental","pubTime":"2026-01-06 02:57","pubTimestamp":1767639420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TSHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 13:57 ET (18:57 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"gpt_icon":0},{"id":"2593426277","title":"Taysha Gene Therapies (TSHA): Revisiting Valuation After TSHA-102 Breakthrough Designation and Trial Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2593426277","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593426277?lang=en_us&edition=fundamental","pubTime":"2025-12-24 10:35","pubTimestamp":1766543738,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (TSHA) has caught investors attention after securing FDA Breakthrough Therapy Designation for its Rett syndrome candidate TSHA-102 and locking in a pivotal REVEAL trial design with an interim analysis aimed at a future filing.\nSee our latest analysis for Taysha Gene Therapies.\nThe excitement around TSHA-102 and the FDA Breakthrough Therapy Designation has helped fuel a powerful rerating, with the stock posting a 30 day share price return of about 29 percent and a roughly...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-revisiting-valuation-after-tsha-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-revisiting-valuation-after-tsha-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TSHA","BK4139"],"gpt_icon":0},{"id":"2593482222","title":"Should Rett Breakthrough Status and Pivotal Trial Plan Require Action From Taysha Gene Therapies (TSHA) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593482222","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593482222?lang=en_us&edition=fundamental","pubTime":"2025-12-22 18:12","pubTimestamp":1766398371,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies recently received FDA Breakthrough Therapy Designation for its Rett syndrome gene therapy candidate TSHA-102 and secured regulatory alignment on the pivotal REVEAL trial protocol, including a planned six-month interim analysis to support a future Biologics License Application.\nThis combination of regulatory recognition and a clearly defined clinical pathway adds important validation to TSHA-102’s potential and clarifies how quickly the Rett program could progress toward...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/should-rett-breakthrough-status-and-pivotal-trial-plan-requi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/should-rett-breakthrough-status-and-pivotal-trial-plan-requi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK4211","TSHA","BK4139"],"gpt_icon":0},{"id":"2589810650","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589810650","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589810650?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:05","pubTimestamp":1764968700,"startTime":"0","endTime":"0","summary":"DALLAS, Dec.  05, 2025  (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200980/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","TSHA","BK4139","BK4135"],"gpt_icon":0},{"id":"2585149793","title":"Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $19 From $13, Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149793","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585149793?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:42","pubTimestamp":1763736138,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (TSHA) has an average rating of buy and mean price target of $10.65, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSHA"],"gpt_icon":0},{"id":"2585907141","title":"Taysha price target raised to $19 from $13 at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2585907141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585907141?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:40","pubTimestamp":1763736043,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Taysha Gene Therapies (TSHA) to $19 from $13 and keeps an Overweight rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/taysha-price-target-raised-to-19-from-13-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/taysha-price-target-raised-to-19-from-13-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA","BK4139"],"gpt_icon":0},{"id":"2584895228","title":"Citizens JMP healthcare analysts hold an analyst/industry conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584895228","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584895228?lang=en_us&edition=fundamental","pubTime":"2025-11-19 01:15","pubTimestamp":1763486139,"startTime":"0","endTime":"0","summary":"Healthcare Analysts discuss regulatory landscape for AAV-based gene therapies (relevant companies (SLDB, TSHA, BNTC, SRPT, QURE, NTLA, CRSP, PRME) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citizens-jmp-healthcare-analysts-hold-an-analyst-industry-conference-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citizens-jmp-healthcare-analysts-hold-an-analyst-industry-conference-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","XLV","LABU","CRSP","XBI","JMP","BK4581","TSHA","LU1861558580.USD","LU1861559042.SGD","BK4139","BK4556","BK4127","BK4585","BK4588"],"gpt_icon":0},{"id":"2583432302","title":"Taysha Gene Therapies Unveils Advances in One-Time Gene Therapy for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2583432302","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583432302?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:49","pubTimestamp":1762976974,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies Inc. has provided an update on TSHA-102, its gene therapy candidate for Rett syndrome. The company highlighted that TSHA-102 is designed as a potential one-time treatment targeting the genetic root cause of Rett syndrome, a rare neurodevelopmental disorder primarily affecting females. The therapy uses an AAV9 capsid and is delivered intrathecally, aiming for broad central nervous system biodistribution while minimizing systemic exposure. The pivotal REVEAL trial is underway, enrolling patients aged 6 to under 22 years, with the primary endpoint focused on the proportion of patients who gain or regain at least one developmental milestone. Interim six-month data may serve as the basis for a biologics license application  with the FDA. Early data from Part A of the REVEAL trial indicated a 100% response rate for the primary endpoint, with no treatment-related serious adverse events or dose-limiting toxicities reported. You can access the full presentation through the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLZbJn2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"gpt_icon":0},{"id":"1129625489","title":"Stock Track | Taysha Gene Therapies Soars 6.56% on Analyst Upgrades and Positive Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1129625489","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129625489?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:42","pubTimestamp":1762353753,"startTime":"0","endTime":"0","summary":"Shares of Taysha Gene Therapies, Inc. (TSHA) are soaring 6.56% in Wednesday's trading session, buoyed by a series of positive analyst ratings and encouraging third-quarter results. The gene therapy...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TSHA"],"gpt_icon":0},{"id":"1161172815","title":"Stock Track | Taysha Gene Therapies Soars 5.39% Pre-market on Positive Analyst Ratings and Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1161172815","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161172815?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:31","pubTimestamp":1762353063,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (TSHA) stock surged 5.39% in pre-market trading on Wednesday, following a series of positive analyst ratings and the release of encouraging third-quarter results. The gene...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TSHA"],"gpt_icon":0},{"id":"2581727236","title":"Taysha Gene Therapies (TSHA) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2581727236","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581727236?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:58","pubTimestamp":1762347480,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee maintained a Buy rating on Taysha Gene Therapies today. The company’s shares closed yesterday at $4.27. Lee cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/taysha-gene-therapies-tsha-receives-a-rating-update-from-a-top-analyst-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/taysha-gene-therapies-tsha-receives-a-rating-update-from-a-top-analyst-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"gpt_icon":0},{"id":"2581845727","title":"Taysha Gene Therapies Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581845727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581845727?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:50","pubTimestamp":1762347000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TSHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 07:50 ET (12:50 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"gpt_icon":0},{"id":"2581488792","title":"Taysha Gene Therapies’ Earnings Call Highlights Progress and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2581488792","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581488792?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:03","pubTimestamp":1762304584,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (($TSHA)) has held its Q3 earnings call. Read on for the main highlights of the call. Taysha Gene Therapies’ recent ear...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-earnings-call-highlights-progress-and-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-earnings-call-highlights-progress-and-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA","PRGS"],"gpt_icon":0},{"id":"2581759759","title":"Taysha Gene Therapies: Advancing REVEAL Study and Mitigating Regulatory Risks Earns Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581759759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581759759?lang=en_us&edition=fundamental","pubTime":"2025-11-05 00:15","pubTimestamp":1762272921,"startTime":"0","endTime":"0","summary":"Analyst Gil Blum of Needham maintained a Buy rating on Taysha Gene Therapies, retaining the price target of $10.00. Gil Blum has given his Buy rati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/taysha-gene-therapies-advancing-reveal-study-and-mitigating-regulatory-risks-earns-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/taysha-gene-therapies-advancing-reveal-study-and-mitigating-regulatory-risks-earns-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"gpt_icon":0},{"id":"1133853946","title":"Stock Track | Taysha Gene Therapies Plummets 5.83% as Q3 Losses Widen and Company Files Mixed Shelf Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=1133853946","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133853946?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:44","pubTimestamp":1762267489,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (TSHA) saw its stock price plummet by 5.83% in pre-market trading on Tuesday, following the release of its third-quarter financial results and the filing of a mixed shelf...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TSHA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tayshagtx.com","stockEarnings":[{"period":"1week","weight":-0.0843},{"period":"1month","weight":-0.1618},{"period":"3month","weight":-0.0339},{"period":"6month","weight":0.7743},{"period":"1year","weight":1.8861},{"period":"ytd","weight":-0.1709}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.17623},{"month":2,"riseRate":0.4,"avgChangeRate":0.109391},{"month":3,"riseRate":0.2,"avgChangeRate":-0.123298},{"month":4,"riseRate":0.4,"avgChangeRate":0.009364},{"month":5,"riseRate":0.4,"avgChangeRate":0.055742},{"month":6,"riseRate":0.2,"avgChangeRate":-0.029545},{"month":7,"riseRate":0.6,"avgChangeRate":0.019307},{"month":8,"riseRate":0.8,"avgChangeRate":0.75256},{"month":9,"riseRate":0.2,"avgChangeRate":-0.089587},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.04036},{"month":11,"riseRate":0.5,"avgChangeRate":0.137875},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.034429}],"exchange":"NASDAQ","name":"Taysha Gene Therapies, Inc.","nameEN":"Taysha Gene Therapies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Taysha Gene Therapies, Inc.,TSHA,Taysha Gene Therapies, Inc.股票,Taysha Gene Therapies, Inc.股票老虎,Taysha Gene Therapies, Inc.股票老虎国际,Taysha Gene Therapies, Inc.行情,Taysha Gene Therapies, Inc.股票行情,Taysha Gene Therapies, Inc.股价,Taysha Gene Therapies, Inc.股市,Taysha Gene Therapies, Inc.股票价格,Taysha Gene Therapies, Inc.股票交易,Taysha Gene Therapies, Inc.股票购买,Taysha Gene Therapies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}